Bard Associates’s Teva Pharmaceuticals TEVA Stock Holding History

Bard Associates’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-3,310	Closed	-$217K	–	168
2015 Q4	$217K	Buy	+3,310	New	+$205K	0.13%	130
2015 Q3	–	Sell	-3,684	Closed	-$218K	–	170
2015 Q2	$218K	Hold	3,684	–	–	0.11%	143
2015 Q1	$230K	Hold	3,684	–	–	0.11%	144
2014 Q4	$212K	Sell	3,684 -120	-3%	-$6.69K	0.1%	151
2014 Q3	$204K	Sell	3,804 -74	-2%	-$3.92K	0.1%	152
2014 Q2	$203K	Sell	3,878 -82	-2%	-$4.19K	0.08%	173
2014 Q1	$209K	Buy	+3,960	New	+$183K	0.09%	169

Other funds holding TEVA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bard Associates's TEVA Position: Q1 2016 in Review

Bard Associates sold out of Teva Pharmaceuticals (TEVA) in Q1 2016, closing a stake of 3,310 shares — an estimated $217K sold.

Bard Associates first reported a position in TEVA in Q1 2014 and held it in 7 quarters. The position peaked at $230K in Q1 2015. 836 funds tracked by Wall St. Rank hold TEVA as of Q1 2016.

Bard Associates reported no remaining Teva Pharmaceuticals position as of Q1 2016 after selling out during the quarter.
Bard Associates sold 3,310 Teva Pharmaceuticals shares in Q1 2016, an estimated $217K.
Bard Associates first reported a position in Teva Pharmaceuticals in Q1 2014 and held it in 7 quarters.
Bard Associates's Teva Pharmaceuticals position peaked at $230K in Q1 2015.
836 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2016.

Based on Bard Associates's 13F filing for Q1 2016, filed 12 May 2016.